|
Intellectual Disability
|
0.120 |
Biomarker
|
group |
BEFREE |
Histone deacetylase 8 (HDAC8) is a class I histone deacetylase implicated as a therapeutic target in various diseases, including cancer, X-linked intellectual disability, and parasitic infections.
|
26013035 |
2015 |
|
Intellectual Disability
|
0.120 |
Biomarker
|
group |
BEFREE |
The present family provides the first evidence for involvement of HDAC8 in a syndromic form of intellectual disability.
|
22889856 |
2012 |
|
Intellectual Disability
|
0.120 |
Biomarker
|
group |
HPO |
|
|
|
|
Autistic Disorder
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
Children with CdLS (5-18 years) were administered normed instruments to characterize autism features (Childhood Autism Rating Scale, CARS), maladaptive behaviors (Aberrant Behavior Checklist), and adaptive skills (Vineland Adaptive Behaviors Scales).
|
24718998 |
2014 |
|
Autistic Disorder
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of HDAC8 is found to be involved in numerous disease conditions such as tumorigenesis, cell proliferation, cancer, viral infections, neuronal disorders and other epigenetic diseases.
|
31074329 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Histone deacetylase 8 (HDAC8) expressions are correlated with a variety of cancer and tumor conditions.
|
31830865 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Human histone deacetylase 8 (HDAC8) is a highly promising target for neuroblastoma and other types of cancer.
|
31630054 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Aim:</b> Simultaneous inhibition of MMP-2 and HDAC8 may be an effective strategy to target cancer.
|
31370697 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, only very limited knowledge exists about the regulation of HDAC8, an established target in multiple types of cancer.
|
30292946 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Histone deacetylase 8 (HDAC8) is involved in malignancy.
|
31530244 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HDAC8 has been established as one of the vital targets as far as the cancer is concerned.
|
31421254 |
2019 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A possible regulation of HDAC8 by redox signal transduction is suggested by the observed relationship between inhibition of reactive oxygen species generating NOX and concomitant increased HDAC8 activity in neuroblastoma tumor cells.
|
30292946 |
2019 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human histone deacetylase 8 (HDAC8) is a highly promising target for neuroblastoma and other types of cancer.
|
31630054 |
2019 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HDAC8, a class I zinc-dependent enzyme, is a potential drug target for treatment of neuroblastoma and T cell lymphoma.
|
31748509 |
2019 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In the light of the importance of HDAC8 in tumorigenesis a possible regulation by redox signaling was investigated using biochemical and biophysical methods combined with site directed mutagenesis.
|
30292946 |
2019 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Histone deacetylase 8 (HDAC8) is a transcriptional regulator and is associated with tumorigenesis of several tumor types.
|
31402267 |
2019 |
|
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A possible regulation of HDAC8 by redox signal transduction is suggested by the observed relationship between inhibition of reactive oxygen species generating NOX and concomitant increased HDAC8 activity in neuroblastoma tumor cells.
|
30292946 |
2019 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human histone deacetylase 8 (HDAC8) is a highly promising target for neuroblastoma and other types of cancer.
|
31630054 |
2019 |
|
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HDAC8, a class I zinc-dependent enzyme, is a potential drug target for treatment of neuroblastoma and T cell lymphoma.
|
31748509 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Aim:</b> Simultaneous inhibition of MMP-2 and HDAC8 may be an effective strategy to target cancer.
|
31370697 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Human histone deacetylase 8 (HDAC8) is a highly promising target for neuroblastoma and other types of cancer.
|
31630054 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Histone deacetylase 8 (HDAC8) expressions are correlated with a variety of cancer and tumor conditions.
|
31830865 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, only very limited knowledge exists about the regulation of HDAC8, an established target in multiple types of cancer.
|
30292946 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
HDAC8 has been established as one of the vital targets as far as the cancer is concerned.
|
31421254 |
2019 |